PMV Pharma Appoints Winston Kung as COO & CFO
Cranbury, New Jersey – December 5, 2017 – PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, today announced the appointment of industry veteran Winston Kung as Chief Operating Officer and Chief Financial Officer.
Prior to joining PMV Pharma, Mr. Kung was Vice President of Business Development and Global Alliances at Celgene, and previously held the position of Chief Business Officer at Celgene Cellular Therapeutics. With his experience leading multiple transactions and a team that managed Celgene’s alliance portfolio of over 100 collaborations, equity investments and company integrations, Mr. Kung will help manage the development of PMV Pharma’s mutant p53 restoration drug pipeline, which got a boost this past February when the company completed a $74 million series B financing round.
“Winston’s track record of deal-making and his financial acumen and leadership will be instrumental as we develop drugs that use a unique mechanism of action to restore mutated p53 proteins to their pivotal role in defending against cancer,” said David Mack, Ph.D., President and CEO of PMV Pharmaceuticals.
“I joined PMV Pharma’s stellar leadership team to help advance the company’s world-class research and emerging pipeline,” Mr. Kung said. “Like many people, I have family and friends who have been impacted by cancer. PMV is developing drugs that may dramatically improve cancer treatment, and I’m excited to be a part of the exceptional team driving this effort.”
Prior to joining Celgene, Mr. Kung held senior positions at Citigroup’s Global Healthcare Investment Banking group and at Lehman Brothers’ Global Mergers and Acquisition group, where he oversaw public and private financings, mergers, acquisitions, spin-outs and financial advisory engagements.
Mr. Kung has also led multiple transactions as part of Genentech’s and Amgen’s Business and Corporate Development groups.
Mr. Kung earned an M.B.A. from Harvard Business School and an A.B. in Biology and International Relations with honors from Brown University.
About PMV Pharma
PMV Pharma was co-founded by Dr. Arnold Levine, one of the discoverers of the p53 protein and a professor emeritus at the Simons Center for Systems Biology at the Institute for Advanced Study. p53 is the most commonly mutated gene in cancer, with over 50 percent of all human tumors containing a p53 mutant protein. PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
Cancer cells often have mutations in p53 that enable them to escape death. PMV Pharma’s unique mechanism of action promises to restore p53 to its normal function, eliminating this escape route and selectively killing the mutant cancer cells without affecting normal tissues. The protein plays a pivotal role in the body’s natural defense mechanism against cancer and induces a highly-organized program of cellular death to prevent the proliferation of potentially cancerous cells.
PMV Pharma is headquartered in Cranbury, New Jersey. The Company has raised over $100 million since its founding in 2013 through investments from Topspin Biotech Fund in association with Euclidean Capital, OrbiMed Advisors, Osage University Partners, and from founding investor InterWest Partners.
Contact
David H. Mack, Ph.D.
President & CEO
PMV Pharmaceuticals, Inc.
dmack@pmvpharma.com
Amiad Finkelthal
Russo Parners
amiad.finkelthal@russopartnersllc.com
(646) 942-5626
(917) 217-1838 mobile
